| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcffd385b763387b8bc29b364cdd0f54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-40 |
| filingDate |
2019-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_738f208366e0bdc8c8d1dcee212b5358
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f32aa3549d1f652facd86222340bd000
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71ea23ae34a31f23f1c3b5148ae8d393 |
| publicationDate |
2022-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022111019-A1 |
| titleOfInvention |
Brca1 modulating compounds, formulations thereof, and uses thereof |
| abstract |
Described herein are BRCA1 modulating compounds and formulations thereof. In some aspects, the BRCA1 modulating compound is a deubiquitinase. In some aspects, the BRCA1 modulating compound is a deubiquitinase inhibitor. as Also described herein are methods of treating a subject in need thereof with a BRCA1 modulating compound or formulation thereof. In some aspects, the subject in need thereof can have a cancer. In some aspects, the subject in need thereof has one or more BRCA1 mutations. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11773425-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022298543-A1 |
| priorityDate |
2018-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |